ArriVent presented positive final proof-of-concept data from the global Phase 1b FURTHER trial for first-line firmonertinib monotherapy in NSCLC patients with EGFR PACC mutations at the WCLC 2025 conference.
Key highlights include 16.0 months median progression free survival (mPFS), confirmed overall response rate (cORR) of 68.2%, and rapid clearance of PACC ctDNA in frontline patients.
The safety profile remains consistent with no new safety signals, and CNS responses with firmonertinib were observed.
Clinically Meaningful PFS and Responses
16.0 months mPFS with firmonertinib, 68.2% cORR, and 42.9% CNS confirmed ORR in front-line patients.
Safety Profile
Well-tolerated and manageable with no new safety signals, common adverse events include diarrhea and rash.
Rapid Clearance of PACC ctDNA
82% and 79% ctDNA clearance in frontline patients treated with firmonertinib at 240 mg and 160 mg, respectively.
- The data reinforces firmonertinib's potential to address unmet needs in EGFR mutant NSCLC treatment.
- Rapid clearance of PACC ctDNA suggests broad activity of firmonertinib in PACC mutant NSCLC.
ArriVent's data shows promising outcomes for firmonertinib in treating NSCLC with EGFR PACC mutations, supporting the initiation of the global registrational ALPACCA Phase 3 trial.